Updated July 27 at 8:27pm
Biotechnology
31 results total, viewing 11 - 20
Venture capitalists invested $124.1 million in Rhode Island companies in 2014, $42 million more than in 2013, and the largest amount to date, according to the MoneyTree Report by PricewaterhouseCoopers LLP and the National Venture Capital Association. more
Voyager Therapeutics, a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system, has entered into a strategic collaboration with MassBiologics of the University of Massachusetts Medical School. more
Moderna Therapeutics has announced another record venture capital investment: $450 million. more
EpiVax Inc. and Novozymes Biopharma entered into a license agreement for the development of treatments for autoimmune diseases, the companies announced on Monday. more
The Champlin Foundations awarded the University of Rhode Island three grants totaling $421,795 to purchase high-tech equipment to advance education and student learning. more
A Cherrystone Angel Group portfolio company, Windgap Medical Inc., was awarded nearly $1 million through a Massachusetts Life Sciences Center accelerator loan program. more
(Updated, 5:14 p.m.) A Cherrystone Angel Group portfolio business has entered into an acquisition agreement of $140 million with a European buyer specializing in bio-analytical testing and genomic services. more
IlluminOss Medical has been issued two patents related to its internal bone fixing system, the company announced Tuesday. more
IlluminOss Medical has received conditional approval from the federal Food and Drug Administration to conduct a clinical trial for treatments of impending and pathologic fractures in the humerus due to metastatic carcinoma. more
Mnemosyne Pharmaceuticals Inc. appointment of Vanessa King as president and CEO. more
« Prev | 1 | 2 | 3 | 4 Next »